USFDA Approved Biosimilars

In the United States, the Food and Drug Administration (FDA) held that new legislation was required to enable them to approve Biosimilars to those biologics originally approved through the PHS Act pathway. Since 2004 the FDA has held a series of public meetings on Biosimilars. The FDA has previously approved biologic products using comparability, for example, Omnitrope in May 2006, but this like Enoxaparin was also to a reference product, Genotropin originally approved as a biologic drug under the FD&C Act.

    Related Conference of USFDA Approved Biosimilars

    May 05-06, 2025

    19th World Drug Delivery Summit

    Vancouver, Canada
    June 16-17, 2025

    3rd Global Online Summit on Nanoscience and Nanotechnology

    Zurich, Switzerland
    June 23-24, 2025

    38th World Congress on Pharmacology

    Paris, France
    August 18-19, 2025

    40th World Congress on Pharmacology and Therapeutics

    Valencia, Spain
    September 22-23, 2025

    Pharma Biotech Expo

    Toronto, Canada
    September 23-24, 2025

    10th International Conference on Future Pharma and Innovations

    Amsterdam, Netherlands
    November 20-21, 2025

    21st Annual Congress on Pharmacology and Toxicology

    Aix-en-Provence, France
    November 27-28, 2025

    4th World Congress on Precision and Personalized Medicine

    Zurich, Switzerland
    November 27-28, 2025

    13th International Conference on Clinical Trials

    Amsterdam, Netherlands
    November 27-28, 2025

    4th World Conference on Pharma Industry and Medical Devices

    Zurich, Switzerland

    USFDA Approved Biosimilars Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in